Efficacy, Safety, and Pump Compatibility of Insulin Aspart Used in Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes
- Bruce W. Bode, MD and
- Poul Strange, MD, PHD
- From the Atlanta Diabetes Associates (B. W.B.), Atlanta, Georgia; and Novo Nordisk Pharmaceuticals (P.S.), Princeton, New Jersey.
- Address correspondence and reprint requests to Bruce W. Bode, MD, Atlanta Diabetes Associates, 77 Collier Rd. NW, Suite 2080, Atlanta GA 30309. E-mail: bbode001{at}aol.com .
Abstract
OBJECTIVE— The purpose of this study was to compare the efficacy, safety, and pump compatibility of insulin aspart (a rapid-acting insulin analog) and buffered regular human insulin in patients with type 1 diabetes undergoing continuous subcutaneous insulin infusion (CSII) therapy.
RESEARCH DESIGN AND METHODS— This was a single-center randomized openlable study. Patients received CSII therapy with insulin aspart (n = 19) or buffered regular human insulin (n = 10) for 7 weeks. Bolus doses of insulin aspart were administered immediately before meals and buffered regular human insulin 30 min before meals.
RESULTS— Insulin aspart and buffered regular human insulin were both effective in controlling average daily blood glucose levels (8.2 ± 1.9 and 8.5 ± 2.1 mmol/l, respectively) (mean ± SD) and maintaining serum fructosamine (343 ± 25.7 and 336 ± 27.4 μmol/l) and HbAlc (6.9 ± 0.6 and 7.1 ± 0.6 %) levels. Possible obstructions and set leakages were infrequently reported in both groups. Similar numbers of patients experienced hypoglycemia (blood glucose <2.5 mmol/l): 14 (74%) insulin aspart patients versus 6 (60%) buffered regular human insulin patients. Patients receiving insulin aspart had fewer hypoglycemic events per patient (2.9) than those patients receiving buffered regular human insulin (6.2). There were no differences between the two insulins in the occurrence of hyperglycemic events (blood glucose >19 mmol/l) or in the number and type of adverse events.
CONCLUSIONS— Insulin aspart and buffered regular human insulin were effective and well tolerated and provided similar pump compatibility when used in CSII therapy.
Footnotes
-
B. W.B. serves on the medical advisory board of Minimed and has received honoraria for serving on speaker's bureaus for Minimed, Novo Nordisk, and Eli Lilly. P.S. holds stock in Novo Nordisk.
-
Abbreviations: CSII, continuous subcutaneous insulin infusion; MDI, multiple daily insulin injection.
-
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.
-
- Accepted September 19, 2000.
- Received June 9, 2000.
- by the American Diabetes Association, Inc.
